Sai Life Sciences Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.

Revenue Growth 20pctPat Growth 25pctEbitda Margin ExpansionResults View source PDF Explain this filing

SAILIFE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+3.7%Reaction day

₹791.95

prior close

₹815.25

announcement price

After-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)-1.3%+4.9% vs market

Pharmaceuticals peers, median of 147sector-0.9%+4.5% vs sector

On the reaction day the stock moved 4.9 pts more than Nifty Smallcap 250 and 4.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+2.9

10m

+2.2

15m

+1.7

30m

+1.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+3.7-1.3+4.9-0.9+4.5

Next day

+11.6-0.8+12.4-0.6+12.2

+10.4-0.8+11.1-0.3+10.6

+14.0-0.2+14.2-0.6+14.6

+12.1-0.6+12.7-0.6+12.7

+13.9+0.7+13.1-0.9+14.8

+15.3+1.9+13.4-0.1+15.4

15d

+3.8+0.5+3.3-0.8+4.6

+7.9+1.1+6.8-1.0+8.9

+8.1+1.2+6.9-1.3+9.4

+14.9+1.6+13.3-4.7+19.6

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 147Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Sai Life Sciences reported strong Q1 FY26 results, with consolidated revenue from operations rising to Rs. 4,964.19 million from Rs. 2,797.23 million in Q1 FY25, a jump of about 77% year-on-year. The company swung to a consolidated profit after tax of Rs. 604.55 million, compared with a loss of Rs. 134.98 million in the same quarter last year. Standalone revenue rose to Rs. 4,830.38 million (vs Rs. 2,644.69 million) and standalone PAT was Rs. 583.70 million versus a prior-year loss. Deloitte Haskins & Sells LLP issued an unmodified limited review conclusion on both sets of results. The board also approved the reappointment of Managing Director & CEO Krishnamraju Kanumuri for another 5-year term from 1 September 2025, subject to shareholder approval, and the 26th AGM is scheduled for 11 September 2025.

Likely market impact

Sharp revenue growth and a return to profitability are positive signals for shareholders, suggesting strong business momentum in the CRDMO segment. Reappointment of the MD & CEO provides leadership continuity, which is generally viewed favorably by the market.